scholarly journals Imprinted tumor suppressor genesARHI andPEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation

Cancer ◽  
2008 ◽  
Vol 112 (7) ◽  
pp. 1489-1502 ◽  
Author(s):  
Weiwei Feng ◽  
Rebecca T. Marquez ◽  
Zhen Lu ◽  
Jinsong Liu ◽  
Karen H. Lu ◽  
...  
Keyword(s):  
Tumor Suppressor ◽  
Loss Of Heterozygosity ◽  
Promoter Methylation ◽  
Ovarian Cancers

scholarly journals Promoter methylation of the SALL2 tumor suppressor gene in ovarian cancers

2012 ◽  
Vol 7 (3) ◽  
pp. 419-427 ◽  
Author(s):  
Chang K. Sung ◽  
Dawei Li ◽  
Erik Andrews ◽  
Ronny Drapkin ◽  
Thomas Benjamin
Keyword(s):  
Tumor Suppressor ◽  
Tumor Suppressor Gene ◽  
Promoter Methylation ◽  
Suppressor Gene ◽  
Ovarian Cancers

GPER is inactivated by promoter methylation and potentially functions as a tumor suppressor in breast cancer

2014 ◽  
Vol 74 (S 01) ◽  
Author(s):  
C Weißenborn ◽  
T Ignatov ◽  
SD Costa ◽  
AC Zenclussen ◽  
A Ignatov
Keyword(s):  
Breast Cancer ◽  
Tumor Suppressor ◽  
Promoter Methylation

Efficacy of decitabine in malignant meningioma cells: relation to promoter demethylation of distinct tumor suppressor and oncogenes and independence from TERT

2020 ◽  
pp. 1-10
Author(s):  
Louise Stögbauer ◽  
Christian Thomas ◽  
Andrea Wagner ◽  
Nils Warneke ◽  
Eva Christine Bunk ◽  
...  
Keyword(s):  
Dna Methylation ◽  
Tumor Suppressor ◽  
Promoter Methylation ◽  
Tumor Suppressor Genes ◽  
Telomerase Activity ◽  
High Grade ◽  
Htert Promoter ◽  
Men 1 ◽  
Meningioma Cell ◽  
Tert Expression

OBJECTIVEChemotherapeutic options for meningiomas refractory to surgery or irradiation are largely unknown. Human telomerase reverse transcriptase (hTERT) promoter methylation with subsequent TERT expression and telomerase activity, key features in oncogenesis, are found in most high-grade meningiomas. Therefore, the authors investigated the impact of the demethylating agent decitabine (5-aza-2ʹ-deoxycytidine) on survival and DNA methylation in meningioma cells.METHODShTERT promoter methylation, telomerase activity, TERT expression, and cell viability and proliferation were investigated prior to and after incubation with decitabine in two benign (HBL-52 and Ben-Men 1) and one malignant (IOMM-Lee) meningioma cell line. The global effects of decitabine on DNA methylation were additionally explored with DNA methylation profiling.RESULTSHigh levels of TERT expression, telomerase activity, and hTERT promoter methylation were found in IOMM-Lee and Ben-Men 1 but not in HBL-52 cells. Decitabine induced a dose-dependent significant decrease of proliferation and viability after incubation with doses from 1 to 10 μM in IOMM-Lee but not in HBL-52 or Ben-Men 1 cells. However, effects in IOMM-Lee cells were not related to TERT expression, telomerase activity, or hTERT promoter methylation. Genome-wide methylation analyses revealed distinct demethylation of 14 DNA regions after drug administration in the decitabine-sensitive IOMM-Lee but not in the decitabine-resistant HBL-52 cells. Differentially methylated regions covered promoter regions of 11 genes, including several oncogenes and tumor suppressor genes that to the authors’ knowledge have not yet been described in meningiomas.CONCLUSIONSDecitabine decreases proliferation and viability in high-grade but not in benign meningioma cell lines. The effects of decitabine are TERT independent but related to DNA methylation changes of promoters of distinct tumor suppressor genes and oncogenes.

Association Between Cyclin D1 Polymorphism with CpG Island Promoter Methylation Status of Tumor Suppressor Genes in Gastric Cancer

2010 ◽  
Vol 55 (12) ◽  
pp. 3449-3457 ◽  
Author(s):  
Tomomitsu Tahara ◽  
Tomoyuki Shibata ◽  
Masakatsu Nakamura ◽  
Hiromi Yamashita ◽  
Daisuke Yoshioka ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Tumor Suppressor ◽  
Cyclin D1 ◽  
Promoter Methylation ◽  
Tumor Suppressor Genes ◽  
Cpg Island ◽  
Methylation Status ◽  
Suppressor Genes ◽  
Promoter Methylation Status

scholarly journals The human plakoglobin gene localizes on chromosome 17q21 and is subjected to loss of heterozygosity in breast and ovarian cancers.

1995 ◽  
Vol 92 (14) ◽  
pp. 6384-6388 ◽  
Author(s):  
H. Aberle ◽  
C. Bierkamp ◽  
D. Torchard ◽  
O. Serova ◽  
T. Wagner ◽  
...  
Keyword(s):  
Loss Of Heterozygosity ◽  
Ovarian Cancers

RASSF1A promoter methylation and 3p21.3 loss of heterozygosity are features of foregut, but not midgut and hindgut, malignant endocrine tumours

2005 ◽  
Vol 206 (4) ◽  
pp. 409-416 ◽  
Author(s):  
S Pizzi ◽  
C Azzoni ◽  
L Bottarelli ◽  
N Campanini ◽  
T D'Adda ◽  
...  
Keyword(s):  
Loss Of Heterozygosity ◽  
Promoter Methylation ◽  
Endocrine Tumours
Sign in / Sign up

Export Citation Format

Share Document